Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fong

Showing results (421-430 of 468) with videos related to

Pageof 47
Sort By:
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
BMC Public Health|September 30, 2015
Rates of motorcycle helmet use and reasons for non-use among adults and children in Luang Prabang, Lao People's Democratic RepublicMichelle C Fong, Jeffrey R Measelle, Jessica L Dwyer, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology|June 26, 2024
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort DEvan Y Yu, Cristiano Ferrario, Mark D Linch, et al.
European Urology|December 17, 2022
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Pageof 47

Showing results (421-430 of 468) with videos related to

Sort By:
Pageof 47
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
BMC Public Health|September 30, 2015
Rates of motorcycle helmet use and reasons for non-use among adults and children in Luang Prabang, Lao People's Democratic RepublicMichelle C Fong, Jeffrey R Measelle, Jessica L Dwyer, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|June 9, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Nature Medicine|January 31, 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology|June 26, 2024
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort DEvan Y Yu, Cristiano Ferrario, Mark D Linch, et al.
European Urology|December 17, 2022
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
Future Oncology (London, England)|July 12, 2024
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancerNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Future Oncology (London, England)|January 30, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 studyKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Pageof 47